← Leaderboards
Peter Alexander Ljubenkov
University Of California, San Francisco
$1,294,957
Attributed
$2,589,914
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $677.1K · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,589,914 · 1
By mechanism
R01$2,589,914 · 1
Top collaborators
- Adam L Boxer4 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Maria Luisa Gorno Tempini$28,653,126
- Bruce L Miller$34,542,477
- Priscilla Y. Hsue$28,957,856
- Glenn-Milo Santos$8,436,377
- Katherine P Rankin$14,490,889
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposConduct Clinical TrialsClinicAttenuatedAutopsyAdverse EventBiologicalBiological AvailabilityBiological MarkersBlindedBloodCharacteristicsBinding ProteinsAmericanAreaClinical DataClinical Dementia Rating ScaleClinical DiagnosisClinical EfficacyClinical ResearchClinical Research SiteClinical TrialsCohortDesign
Grant awards (4)
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP$633,691
R01 · FY2024 · AG · contact PI
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP$638,870
R01 · FY2023 · AG · contact PI
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP$640,216
R01 · FY2022 · AG · contact PI
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP$677,137
R01 · FY2021 · AG · contact PI